Global TNF Biosimilars Market 2027: Top Key Players Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko

Tumor necrosis factors are a group of cytokines which are secreted by macrophages and may induce cell death of certain tumor cell lines which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called as TNF blockers. Currently only five anti-TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of Anti-TNF biosimilar market. Moreover, rising incidence and prevalence of rheumatic disease and switching trend from traditional treatment to biologic therapy have boosted the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.

Request For Sample @ https://bit.ly/2C5DdwF

The global anti-TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of treatment the global market is further sub segmented into adalimumab biosimilar, infliximab biosimilar, certolizumab biosimilar, etanercept biosimilar, and golimumab biosimilar. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. Humira is protected with more than 100 patents in US which make the entry of biosimilars complicated in the US market however, biosimilar of adalimumab is expected to launch in the US by 2023 and in Europe in 2018 which drives the growth of the market during forecast period. TNF Inhibitors market is already saturated thus certolizumab biosimilar and golimumab biosimilar segments expected to hold minimal share of the market due to late entry of biosimilars in the market. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to increase in number internet user and ease of use.

At regional level, the global anti-TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global Anti-TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demad for biosimilars propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities for the Anti-TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of anti-TNF in low income countries.

Request For Table Of Content (TOC) @ https://bit.ly/2C5DdwF

Some of the market players leading the global Anti-TNF biosimilars market include Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko, and other prominent players.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.